Rate My Professor Ashleigh Hull

Dr. Ashleigh Hull serves as Lecturer in Nuclear Medicine within the College of Health, School of Allied Health and Human Performance at Adelaide University. She earned her PhD in Medical Radiation Science and undergraduate degree from the University of South Australia. A registered nuclear medicine technologist, she possesses clinical experience that informs her research and teaching, facilitating observation of the translational pathway from research to clinical application in nuclear medicine and theranostics.

Hull's research centers on the development and preclinical testing of targeted radionuclide therapies, with a focus on novel radioimmunoconjugates for pancreatic ductal adenocarcinoma (PDAC) and glioblastoma multiforme. Her PhD investigated preclinical development of radioimmunoconjugates for pancreatic cancer treatment. Notable publications include 'Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration' (EJNMMI Radiopharmacy and Chemistry, 2023), 'In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer' (EJNMMI Radiopharmacy and Chemistry, 2023), 'Preliminary development and testing of C595 radioimmunoconjugates for targeting MUC1 cancer epitopes in pancreatic ductal adenocarcinoma' (Cells, 2022), 'Radioimmunotherapy of pancreatic ductal adenocarcinoma: a review of the current status of literature' (Cancers, 2020), 'Radioimmunotherapy of glioblastoma multiforme - current status and future prospects' (Critical Reviews in Oncology/Hematology, 2021), 'The expression profile and textural characteristics of C595-reactive MUC1 in pancreatic ductal adenocarcinoma for targeted radionuclide therapy' (Cancers, 2021), and 'Biological Principles behind Targeted Radionuclide Therapy for Cancer' (Radiotheranostics - A Primer for Medical Physicists, 2024). She was the 2021 ANSTO/ANZSNM Research Grant winner for preclinical studies of MUC1 targeted alpha therapy for pancreatic cancer. Hull teaches Nuclear Medicine Studies 3 (RADI 3006), Nuclear Medicine Studies 4 (RADI 3007), Nuclear Medicine Clinical Practice 4 (HLTH 4012), Nuclear Medicine Honours Clinical Practice 4 (RADI 4008), and Nuclear Medicine Professional Entry Practice 2 (RADI 4010). She is eligible to co-supervise Masters and PhD students and available for media comment.